United States - English - NLM (National Library of Medicine)

unither manufacturing, llc - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 10 mg - metadate cd is contraindicated in patients with marked anxiety, tension and agitation, since the drug may aggravate these symptoms. metadate cd is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product. metadate cd contains sucrose. therefore, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine. metadate cd is contraindicated in patients with glaucoma. metadate cd is contraindicated in patients with motor tics or with a family history or diagnosis of tourette's syndrome (see adverse reactions). metadate cd is contraindicated during treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result). metadate cd is contraindicated in patients with severe hypertension, angina pectoris, cardiac arrhythmias, heart failure, recent myocardial infarc

United States - English - NLM (National Library of Medicine)

unither manufacturing, llc - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 20 mg - attention deficit disorders (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. metadate er is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. specific etiology of th

United States - English - NLM (National Library of Medicine)

unither manufacturing, llc - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 5 mg - attention deficit disorders (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. speci

United States - English - NLM (National Library of Medicine)

unither manufacturing llc - hydrocodone (unii: 6yks4y3wq7) (hydrocodone - unii:6yks4y3wq7), chlorpheniramine (unii: 3u6io1965u) (chlorpheniramine - unii:3u6io1965u) - hydrocodone bitartrate 10 mg in 5 ml - tussionex pennkinetic extended-release suspension is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older. tussionex pennkinetic extended-release suspension is contraindicated in patients with a known allergy or sensitivity to hydrocodone or chlorpheniramine. the use of tussionex pennkinetic extended-release suspension is contraindicated in children less than 6 years of age due to the risk of fatal respiratory depression. tussionex pennkinetic extended-release suspension is a schedule ii narcotic. psychic dependence, physical dependence and tolerance may develop upon repeated administration of narcotics; therefore, tussionex pennkinetic extended-release suspension should be prescribed and administered with caution. however, psychic dependence is unlikely to develop when tussionex pennkinetic extended-release suspension is used for a short time for the treatment of cough. physical dependence, the condition in which contin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

unither pharmaceuticals s.a. - ambroxol hydrochloride 6 mg/ml - oral solution - 30 mg/5 ml - ambroxol hydrochloride 6 mg/ml - ambroxol

United Kingdom - English - myHealthbox

intrapharm laboratories limited - carbocisteine - oral solution in sachet - 750mg/10m - mucolytic - it is indicated in adults and children over 15 years for recent respiratory disorder with expectoration difficulties (difficulty rejecting by spitting out sputum).

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

unither industries - estriol - estriol....0.5 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

u.c.b., belgium - lacosamide - syrup - 10 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ucb pharma s.a., belgium - brivaracetam - oral solution - 10 mg/ml